328 related articles for article (PubMed ID: 12672070)
1. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
3. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
[TBL] [Abstract][Full Text] [Related]
4. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
Chang ZL; Netski D; Thorkildson P; Kozel TR
Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
[TBL] [Abstract][Full Text] [Related]
5. Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans.
Retini C; Kozel TR; Pietrella D; Monari C; Bistoni F; Vecchiarelli A
Infect Immun; 2001 Oct; 69(10):6064-73. PubMed ID: 11553544
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway.
Chiapello LS; Baronetti JL; Garro AP; Spesso MF; Masih DT
Int Immunol; 2008 Dec; 20(12):1527-41. PubMed ID: 18927317
[TBL] [Abstract][Full Text] [Related]
7. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Parra C; González JM; Castañeda E; Fiorentino S
Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
[TBL] [Abstract][Full Text] [Related]
8. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
10. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
Li RK; Mitchell TG
J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525
[TBL] [Abstract][Full Text] [Related]
11. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal capsular glucuronoxylomannan reduces ischaemia-related neutrophil influx.
Ellerbroek PM; Schoemaker RG; van Veghel R; Hoepelman AI; Coenjaerts FE
Eur J Clin Invest; 2004 Sep; 34(9):631-40. PubMed ID: 15379763
[TBL] [Abstract][Full Text] [Related]
13. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
14. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
Yauch LE; Lam JS; Levitz SM
PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
[TBL] [Abstract][Full Text] [Related]
15. O-acetylation of cryptococcal capsular glucuronoxylomannan is essential for interference with neutrophil migration.
Ellerbroek PM; Lefeber DJ; van Veghel R; Scharringa J; Brouwer E; Gerwig GJ; Janbon G; Hoepelman AI; Coenjaerts FE
J Immunol; 2004 Dec; 173(12):7513-20. PubMed ID: 15585878
[TBL] [Abstract][Full Text] [Related]
16. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
19. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
20. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS.
Ikeda R; Maeda T
Carbohydr Res; 2004 Feb; 339(3):503-9. PubMed ID: 15013387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
